MiNK Therapeutics (NASDAQ:INKT – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect MiNK Therapeutics to post earnings of ($0.50) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
MiNK Therapeutics Stock Up 6.4 %
INKT stock opened at $8.49 on Friday. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The stock’s 50 day moving average is $8.94 and its two-hundred day moving average is $7.74. The company has a market capitalization of $33.65 million, a PE ratio of -2.18 and a beta of 0.16.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lifted their price objective on MiNK Therapeutics from $9.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Stock Sentiment Analysis: How it Works
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Short a Stock in 5 Easy Steps
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
